WuXi Biologics Completes IPO and Begins Trading on the Hong Kong Stock Exchange

On June 13, 2017, WuXi Biologics (Cayman) Inc., a leading open-access R&D capability and biologics technology platform company—and a WuXiAppTec Group company—completed its initial public offering of 192,982,500 shares at an offering price of HK$20.60 per share, for a total offering size of approximately HK$3.98 billion (approximately HK$4.57 billion if the underwriters fully exercise their over-allotment option to purchase 28,947,000 additional shares). The shares began trading on the Main Board of the Stock Exchange of Hong Kong on June 13, 2017. According to multiple news reports, the WuXi Biologics IPO is the largest new listing in Hong Kong so far in 2017. Wilson Sonsini Goodrich & Rosati acted as U.S. and Hong Kong counsel to WuXi Biologics in the offering and listing.

Merrill Lynch International, Morgan Stanley Asia Limited, and China Merchants Securities (HK) Co., Limited acted as the representatives to the underwriters in the offering.

The WSGR team advising WuXi Biologics in the offering includes primarily:

U.S. Corporate:
Weiheng Chen, Partner
Jie Zhu, Partner
Ke Li, Associate

Hong Kong Corporate:
Ethan Jin, Partner
Can Yin, Associate
Katherine Wang, Special Associate
Dong Huang, PRC Legal Consultant

Jonathan Zhu, Partner
Myra Sutanto Shen, Partner

For more information, please see WuXi Biologics' press release.